Bright Minds Biosciences (DRUG) Operating Leases (2022 - 2025)

Bright Minds Biosciences has reported Operating Leases for 4 years, with the latest figure at $12006.9 in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases fell 84.76% year-over-year to $12006.9; the trailing twelve-month figure through Dec 2025 stood at $12006.9 (down 84.76% YoY), and the FY2025 full-year result was $29973.0, up 3.31% from the prior year.
• Operating Leases for Q4 2025 stood at $12006.9, down from $29973.0 in the prior quarter.
• The five-year high for Operating Leases was $107276.2 in Q3 2022, with the low at $10434.2 in Q2 2023.
• Historically, Operating Leases has averaged $44065.4 across 4 years, with a median of $35085.2 in 2022.
• The largest YoY upside for Operating Leases was 3.31% in 2025 against a maximum downside of 84.76% in 2025.
• Bright Minds Biosciences' Operating Leases stood at $40197.5 in 2022, then sank by 74.04% to $10434.2 in 2023, then soared by 655.13% to $78792.1 in 2024, then tumbled by 84.76% to $12006.9 in 2025.
• The last three Operating Leases figures came in at $12006.9 (Q4 2025), $29973.0 (Q3 2025), and $45353.9 (Q2 2025), per Business Quant data.